Company intelligence / Profile preview

Meilleur Technologies

Knoxville, Tennessee, United States

Ownership: Private
Development stage: Other

Overview

Meilleur Technologies was a privately held U.S.-based biotech focused on imaging biomarkers—primarily radiopharmaceutical PET agents for neurodegenerative disease, especially Alzheimer's. Lead product: NAV-4694, a Phase 3 F-18 labeled beta-amyloid imaging agent for use in PET scans to identify amyloid plaques, hallmark of Alzheimer's disease. Acquired by Lantheus in July 2024 for their NAV-4694 program; Lantheus now holds global exclusive rights.

Therapeutic areas: Neurology
Modalities: RadiopharmaceuticalImaging biomarker
Industry: Biotech

Partnerships

Navidea BiopharmaceuticalsPharmaLogic HoldingsAlzheimer’s Disease Neuroimaging Initiative 4 (ADNI4)

Beyond the preview

Go deeper on Meilleur Technologies.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Meilleur Technologies.

Explore the full profile